Patent ID: 6299875
Filing Date: 2001-10-09
Classification: A61K,A61P,C07K,Y10S

Abstract:
A method of inhibiting an allergic response comprisingadministering to an individual in need thereof an effective amount of a composition that prevents clinically significant allergen-induced mast cell activation, which composition comprisesa pharmaceutically acceptable carrier; anda compound that binds to the IgE binding site of an Fc.epsilon. receptor to prevent occupancy of the receptor by native IgE, which compound cannot be cross-linked by antigen, and does not elicit an immune reaction,wherein the composition is administered in a dosage effective to maintain a serum concentration of the compound equivalent to at least 5.times.10.sup.-6 g IgE fragments/ml or a dosage equivalent to between 0.4 and 0.8 g IgE fragments/70 kg person/day, and whereinthe composition is administered for a period of time of at least one month effective to displace native IgE from the individual's mast cells.